Advanced Cancers Clinical Trial
Official title:
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
The goal of this clinical research study is to find out if using the tracer (liquid used in imaging scans) [18F]fluciclatide in positron emission tomography / computed tomography (PET/CT) scans will help researchers learn more quickly if the disease is responding to treatment.
PET/CT Scans:
If you are found eligible to take part in this study, you will have a PET/CT scan at your
treatment baseline visit, about 1 week before your first cycle of chemotherapy. You will
then have a second PET/CT scan at the end of your first cycle of chemotherapy (about 3-4
weeks after starting chemotherapy).
For up to 6 hours before the PET/CT scan, you must not eat or drink anything except water. A
small needle and tube will be placed in your arm, and you will receive an injection of a
very small amount of a mildly radioactive material into your bloodstream (the
investigational tracer, [18F]fluciclatide). The radioactive nature of this injected material
allows the scanner to "see" it in certain places in your body. After the injection, you will
need to rest quietly until it is time for the scan. The amount of rest time may vary, but be
prepared to wait for between 45 and 90 minutes. During the scan, you will lie flat on your
back on a table. The scan itself may last up to 1 hour.
Each PET/CT imaging session will last about 4 hours total from the time you arrive at the
clinic until you are discharged and allowed to go home. You may be discharged 30 minutes
after the scan is complete, if the doctor thinks you are clinically stable and it is safe
for you to leave.
Study Visits:
If the following tests are already being performed as part of the clinical research study
you are participating in or as part of standard care, they will not need to be repeated for
this study.
Baseline Visit (before the first PET/CT is performed):
- You will have a physical exam.
- Blood (about 3 tablespoons) will be drawn for routine tests.
- If you can become pregnant, urine will be collected for a pregnancy test. To take part
in this study, you must not be pregnant.
End of Cycle 1 (before the second PET/CT is performed):
-Blood (about 3 tablespoons) will be drawn for routine tests.
About 24 hours after each PET/CT is performed, the study staff will call you by telephone to
ask about your health status and any side effects you may be experiencing.
Anytime within the next month after the second PET/CT scan, blood (about 3 tablespoons) will
be drawn for routine tests.
When your chemotherapy is over, you will have a third PET/CT scan as part of your standard
care, and an FDG tracer will be used for that scan.
Length of Participation:
Your study participation will end about 6 weeks after your second PET/CT scan is performed.
This is an investigational study. [18F]Fluciclatide is not FDA approved or commercially
available. At this time, it is only being used in research.
Up to 50 patients will take part in this research study. All will be enrolled at MD
Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
Terminated |
NCT00499382 -
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
|
N/A | |
Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A |